Pfizer (NYSE:PFE) Says Adios to Lung Drug Thelin, Recalls it Globally

Pfizer (NYSE:PFE) had ended its trials for its lung drug Thelin, recalling it from around the world because of its connection to causing damage to the liver.

Bank of America (NYSE:BAC) analyst Brigitte de Lima noted, “Thelin was not expected to become a major player” for the very reason it has been recalled: safety concerns.

Thelin was being sold in Canada, Australia, and the European Union. In the first three quarters of 2010, it has generated $44.4 million in revenue for Pfizer.

Thelin became part of Pfizer's pipeline when they acquired Encysive in 2008.

Pfizer said the drug shouldn't be prescribed to any new patients, and for patients already taking it, they recommend transferring to a different solution.

The European Medicines Agency told patients to continue taking the drug until they can see their doctor.